Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...
The core foundation of precision medicine, and in turn, precision oncology, is a personalized approach to treatment that focuses on targeting specific molecular features that impact how cancer cells ...
Allogeneic Vaccination With a B7.1 HLA-A Gene-Modified Adenocarcinoma Cell Line in Patients With Advanced Non–Small-Cell Lung Cancer The incidence of prostate cancer is frequent, occurring in almost ...
Real world outcomes of darolutamide efficacy and safety in treating non-metastatic and metastatic hormone-sensitive prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...
The biotech start-up Cure51 is working on the first global molecular database of exceptional survivors of cancer - Copyright AFP JUAN MABROMATA The biotech start-up ...
Distinguishing cancer cells from healthy cells is a central challenge in cancer treatment. Ideal therapies selectively kill cancer cells while leaving healthy cells healthy and able to perform their ...
A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the ...
Researchers found that analyzing certain chemokine levels may help explain racial disparities in prostate cancer lethality, and that neutralizing such chemokines could potentially benefit prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results